Q3 2025 Madrigal Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Madrigal Pharmaceuticals Inc (MDGL) reported strong third-quarter net sales of $287 million, marking a 35% increase quarter over quarter.
- The company has successfully treated over 29,500 patients with ResDFRA, with more than 10,000 healthcare providers prescribing the medication.
- Madrigal Pharmaceuticals Inc (MDGL) has made significant progress in payer contracting for 2026, securing broad first-line access with no step edit requirements.
- The company has expanded its global presence with the launch of ResDFRA in Germany following European approval.
- Madrigal Pharmaceuticals Inc (MDGL) is advancing its pipeline with the Phase 3 Maestro Nash outcomes trial and exploring combination strategies with new assets like the oral GLP-1 MGL 2,086.
- The company faces challenges with the high gross-to-net impact expected to rise to the high 30% range in 2026, affecting profitability.
- There are concerns about the long-term competitive landscape as large pharmaceutical companies enter the MAS market.
- Madrigal Pharmaceuticals Inc (MDGL) is still in the early stages of its European expansion, with significant time and resources required to establish market presence.
- The company reported increased R&D expenses due to a one-time $117 million expense associated with a global licensing agreement.
- There is uncertainty regarding the impact of Novo's marketing campaign on the MAS market and the potential increase in diagnosed patients.
Good morning and thank you for standing by. Welcome to the Madrigal Pharmaceutical 3rd quarter 2025 earnings conference call. At this time, all participants are listen-only mode. After the speaker's presentation, there'll be a question answer session. As a reminder, today's conference call is being recorded. I'd like to introduce Ms. Tina Ventura, Chief Investor relations officer, please go ahead.
Thanks, Marvin. Good morning, everyone, and thank you for joining us to discuss Madrigal's 3rd quarter, 2025 earnings.
We issued a press release this morning and posted a slide deck that accompanies this webcast on the investor relations section of our website.
On the call with me today is Bill Sybel, Chief Executive Officer, Dave Sorgal, Chief Medical Officer, and Marty Dear, Chief Financial Officer.
They will provide prepared remarks and then we'll take your questions.
Please note on slide 2, we will be making certain forward-looking statements today.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
